उत्पाद विवरण
Dacoplice 45 mg Tablet is a targeted therapy designed for patients diagnosed with advanced or metastatic non-squamous non-small cell lung cancer, serving as an effective first-line treatment or a subsequent option following the failure of standard chemotherapy. This medication specifically targets tumors with identifiable mutations, including the epidermal growth factor receptor (EGFR) exon 19 deletion and the L858R substitution mutation, thereby enhancing treatment efficacy. It operates by inhibiting cancer cell growth, leading to improved patient outcomes. However, it is important to note that Dacoplice is not recommended for use in children or adolescents, as its safety and efficacy in these populations have not been established. Before starting treatment, patients should discuss potential side effects and contraindications with their healthcare provider to ensure the best therapeutic approach. As a vital component in the management of specific lung cancers, Dacoplice offers hope to those navigating complex treatment pathways. Always consult with a qualified healthcare professional for personalized advice and to determine if Dacoplice is the right choice for your cancer treatment plan.
Send Email 
जांच भेजें
जांच भेजें
एसएमएस भेजें
English
Spanish
French
German
Italian
Chinese (Simplified)
Japanese
Korean
Arabic
Portuguese